Market capitalization | $1.01b |
Enterprise Value | $760.73m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 3.67 |
P/S ratio (TTM) P/S ratio | 4.85 |
P/B ratio (TTM) P/B ratio | 2.76 |
Revenue growth (TTM) Revenue growth | 29.35% |
Revenue (TTM) Revenue | $207.11m |
As a Free StocksGuide user, you can view scores for all 6,912 stocks worldwide.
7 Analysts have issued a Aurinia Pharmaceuticals Inc. forecast:
7 Analysts have issued a Aurinia Pharmaceuticals Inc. forecast:
Jun '24 |
+/-
%
|
||
Revenue | 57 57 |
38%
38%
|
|
Gross Profit | 48 48 |
22%
22%
|
|
EBITDA | 4.11 4.11 |
122%
122%
|
EBIT (Operating Income) EBIT | -0.73 -0.73 |
96%
96%
|
Net Profit | 0.72 0.72 |
106%
106%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.
Head office | Canada |
CEO | Peter Greenleaf |
Employees | 300 |
Founded | 1993 |
Website | www.auriniapharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.